SCHEMBL29324174

SCHEMBL29324174

C[C@@H]1CC[C@@H](c2cnn(Cc3ccccc3)c2)NC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.44
AURKA O14965 1/20 0.40
ITK Q08881 1/20 0.40
CREBBP Q92793 3/20 0.39
ACHE P22303 1/20 0.39
BRD4 O60885 1/20 0.39
PRMT5 O14744 1/20 0.38
ADORA2A P29274 4/20 0.38
ADORA1 P30542 4/20 0.38
KDM1A O60341 2/20 0.37
HDAC6 Q9UBN7 2/20 0.37
SCD O00767 1/20 0.36
SCD5 Q86SK9 1/20 0.36
ADORA2B P29275 3/20 0.36
ADORA3 P0DMS8 2/20 0.36
HDAC8 Q9BY41 1/20 0.36
RPS6KA2 Q15349 1/20 0.36
ALK Q9UM73 1/20 0.36
TCF4 P15884 1/20 0.36
CTNNB1 P35222 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29081773 0.85 ADORA2B (0.43) L3MBTL1CREBBPBRD4PRMT5ADORA2A
SCHEMBL29081774 0.85 ADORA2B (0.43) L3MBTL1CREBBPBRD4PRMT5ADORA2A
SCHEMBL29324286 0.85 ADORA2B (0.43) L3MBTL1CREBBPBRD4PRMT5ADORA2A
SCHEMBL24364183 0.79 CYP2C19 (0.48) L3MBTL1CREBBPPRMT5ADORA2AADORA1
SCHEMBL16545298 0.77 L3MBTL1 (0.48) L3MBTL1AURKAITKCREBBPACHE
SCHEMBL30471218 0.74 SMN1; SMN2 (0.42)
SCHEMBL24233795 0.74 SMN1; SMN2 (0.42)
SCHEMBL14359968 0.74 SMN1; SMN2 (0.42)
SCHEMBL21192852 0.73 L3MBTL1 (0.43) L3MBTL1AURKAITKCREBBPBRD4
SCHEMBL21193640 0.73 L3MBTL1 (0.43) L3MBTL1AURKAITKCREBBPBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 L3MBTL1 3066/4885AURKA 4715/4885ITK 4118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.